Home › Trial NCT00702052
Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy
- Trial IDNCT00702052
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorNovartis Pharmaceuticals
- Enrollment58
- Start date2008-08-22
- ConditionsLymphoma, Mantle- Cell
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.